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ABSTRACT 
Objectives: Although decreasing in frequency, Pseudomonas 
aeruginosa bacteremia is still a major challenge for neutropenic 
cancer patients. In patients with hematologic malignancies, the 
prognosis of F! aeruginosa bacteremia is particularly poor due 
to the prolonged and severe neutropenia, mucosal damage, 
and other defects in immunity related both to the underlying dis- 
ease and to the cytotoxic therapy. 
Methods: To verify the outcome of P aeruginosa bacteremia 
and to try to define possible prognostic factors, the authors 
reviewed the medical records of 127 consecutive episodes of 
P aeruginosa bacteremia observed in the hematologic unit of 
the Verona University School of Medicine. 
Results: Presence of pneumonia and septic shock, persistence 
and severity of neutropenia, delayed and inappropriate antibiotic 
therapy, and unresponsive underlying disease had negative 
impact on clinical outcome of f? aeruginosa bacteremia. 
Conclusions: With recognition of the risk factors and more 
careful management, the prognosis of P aeruginosa bacteremia 
in neutropenic patients with hematologic malignancies has 
improved in recent years. 
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Infections due to aerobic gram-negative organisms and 
in particular to Pseudomonas aeruginosa cause a high 
rate of mortality in immunocompromised hosts.l-* Among 
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E! aeruginosa infections, bacteremia is the most chal- 
lenging to the patients and implies a high mortality rate, 
especially if associated with organ invasion. In a previ- 
ous study on gram-negative bacteremias at the Verona 
University School of Medicine Department of Hema- 
tology, a disturbingly high mortality rate was noted in 
granulocytopenic patients with Pseudomonas sep- 
ticemia.9 Since then, diagnostic and therapeutic 
approaches have been improved, with early implemen- 
tation of diagnostic maneuvers and early initiation of 
empirical antibacterial therapy, based on the study of the 
commonly offending pathogens. Highly active 
antipseudomonal drugs, in particular amikacin; third gen- 
eration cephalosporins, notably ceftazidime; and more 
recently, imipenem-cilastatin, have been routinely com- 
bined in the ensuing years. 
To verify whether these new modalities of treatment 
have had an impact on clinical outcome of I? aeruginosa 
bacteremia in patients with hematologic malignancies 
and if there are particular prognostic factors, the authors 
analyzed 127 consecutive episodes of I? aeruginosa bac- 
teremia that occurred in the hematologic unit between 
April 1976 and December 1995. 
The literature reports a variety of studies, most of 
which originate in the United States, on P aeruginosa 
bacteremia in patients with maIignancies.7~8Jo-24 However, 
few of these reports relate exclusively to patients with 
hematologic malignancies which are known to imply fre- 
quently an association of risk factors.18J9J2J3 
MATERIAL AND METHODS 
The medical records of all patients who experienced P 
aeruginosa bacteremia in the hematologic unit between 
April I976 and December 1995 were reviewed. All 
patients who had appropriate signs and symptoms of sys- 
temic infection in association with one or more ante 
mortem positive blood specimens for P aeruginosa are 
included in this study 
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Definitions 
Associated infection was defined a microbiologically or 
clinically proven site of infection concomitant to posi- 
tive blood cultures. At the onset of bacteremia, the 
patients were classified in four groups according to the 
neutrophil count: less than 100/1~,L, between 100 and 
500/1_~L, between 501 and 1000 ~J,L, and more than 
lOOO/kL. The neutrophil count was considered to have 
increased if at the end of the episode the count was in 
a higher group compared to the initial count. The patient 
was considered in septic shock if his or her previous nor- 
mal blood pressure fell under 90/60 mmHg in presence 
of oliguria or anuria. The bacteremia was considered 
nosocomial if it occurred after 5 days of hospitalization. 
Patients were considered to be cured of their infection 
if they became afebrile and all the clinical and laboratory 
signs of infection disappeared. Death occurring within 
21 days after the first positive blood culture was consid- 
ered to be due to I? aeruginosa bacteremia, even if other 
causes of death were present, such as other infections, 
hemorrhage, or progression of disease. Empirical anti- 
biotic therapy was defined appropriate if it included at 
least an antipseudomonal beta lactam or an aminoglyco- 
side antibiotic administered at appropriate dosage for at 
least 24 hourszO Antibiotic sensitivity tests were per- 
formed in vitro on positive subcultures with antibiotic- 
impregnated disks, using the Kirby-Bauer technique. 
Delay in antibiotic therapy was defined as an inter- 
val of 12 or more hours between the onset of the signs 
of infection and the start of antibiotic therapy. To evalu- 
ate the outcome in relation to the antibiotic therapy, the 
patients were divided into two groups: those treated 
before 1984, who received a broad-spectrum antibiotic 
without third generation cephalosporin or imipenem- 
cilastatin, and those treated since 1984 with third gen- 
eration cephalosporin or imipenem-cilastatin alone or 
associated with aminoglycoside. The two groups of 
patients were compared. The first group included 38 
episodes observed between 1976 and 1983; the second, 
89 episodes seen between 1984 and 1995. 
Statistical Analysis 
Statistical analysis was performed using chi-square test 
and Fisher’s exact test. 
RESULTS 
One hundred and twenty-seven consecutive episodes of 
l? aeruginosa bacteremia were diagnosed among 119 
patients (52 females, 67 males) at the University of Verona 
Hematologic Unit. The mean age of patients was 47 years 
(range = 12-80 y). All but one patient had a hematologic 
malignancy. The majority of episodes of bacteremia 
occurred in patients with acute leukemia: 85 of 127 (67%) 
Table 1. Relation between Pneumonia and Outcome 
in Episodes of Pseudomonas aeruginosa Bacteremia 
Episodes Mortalify 
(n = 1277 (n = 49) (38.5%) 
Bacteremia with pneumonia 61 35/61 (57) 
Bacteremia without pneumonia 66 14/66 (21)* 
*Bacteremia with pneumonia vs. bacteremia without pneumonia = P < 0.0001, 
chi-square. 
(acute nonlymphocytic leukemia: n = 47; acute lympho- 
cytic leukemia: n = 31; blastic transformation of chronic 
myelogenous leukemia: n = 7). The remaining episodes 
occurred in patients with non-Hodgkin lymphoma 
(n = 26) Hodgkin disease (n = 4) chronic lymphocytic 
leukemia (n = 4), multiple myeloma (n = 6) malignant his- 
tiocytosis (n = l), severe aplastic anemia (n = 1). Twelve 
patients each had two episodes of I! aeruginosa bac- 
teremia, 8 of the 12 during different periods of hospital- 
ization. Fifty-three episodes (42%) occurred in patients 
with hematologic disease in relapse or not responsive to 
chemotherapy. 
Associated Infections 
In 78 of 127 episodes (61%) the bacteremia was associ- 
ated with other microbiologically or clinically docu- 
mented sites of infection. Bacteremia alone was diagnosed 
in the remaining 49 episodes. Pneumonia, alone or asso- 
ciated with some other site of infection, was the most 
common type of concomitant infection (61/127,48%), 
and it was related to a high mortality (Table 1). Cuta- 
neous lesions defined as ecthyma gangrenosum were 
observed in 12 of 127 episodes (9.5%). 
Mortality 
The overall mortality was 49 of 127 (38%) and decreased 
from 27 of 38 (71%) in the first period of the study to 22 
of 89 (25%) in the second period (P < 0.0001, &i-square). 
Granulocytopenia 
During the bacteremia, in all but eight episodes the 
patients experienced neutropenia (polymorphonuclear 
cells [PMN] <100O/l~L), including six patients not 
Table 2. Relation between Neutropenia and Outcome 
in Episodes of Pseudomonas aeruginosa Bacteremia 
Deaths/Episodes 
/n&i/ Count Deaths/Episodes PMN Decrease PMN Rise* 
(PMN/kL) (49/727) (38.5%) (42/66) (64%) (7161) (11.5%) 
<lOO 16157 (28) 14/22 2135 
100-500 15/37 (40.5) 13/21 2/l 6 
501-1000 11 /I 9 (58.0) 11/17 o/2 
>I000 7/l 4 (50.0) 4/6 318 
PMN = polymorphonuclear cells. 
*Deaths/Episodes: PMN decrease vs. PMN rise = P < 0.0001, chi-square. 
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Table 3. Relation between Septic Shock and Outcome 
in Episodes of Pseudomonas aeruginosa Bacteremia 
Patients Deaths 
(n = 127) (100%) (49/127) (38.5%) 
Septic shock 46 (36) 30/46 (65.0) 
No septic shock 81 (64) 19/81 (23.0)* 
*Deaths: septic shock vs. no septic shock = P < 0.0001, chi-square. 
neutropenic at the onset but who became neutropenic 
soon thereafter. The neutrophil count at the onset of the 
episode, the evolution of neutropenia during the episode, 
and its relation with death are reported in Table 2. At the 
onset of the bacteremia, 94 of 127 (74%) patients had 
less than 500 PMN/~.LL; among these (57/127, 45%) had 
less than 100 PMN/~.LL. Of the neutropenic patients, 61 of 
113 (54%) subsequently had a granulocyte recovery to 
above 1000 PMN&L. The mortality was 11.5% in patients 
with granulocyte recovery, as opposed to 64% in patients 
who remained neutropenic (P < 0.0001, chi-square). 
Shock 
Forty-six of 127 (36%) episodes of bacteremia were com- 
plicated by septic shock (Table 3). The mortality rate in 
episodes with septic shock was 65% (30/46) whereas in 
the 81 episodes without shock it was 23% (19/Sl) 
(P c 0.0001, chi-square). The majority of the episodes 
with shock were observed in the first period of the study 
(1976-1983) (Table 4). 
Polymicrobial Bacteremia 
Twenty-six of 127 (20.5%) episodes of bacteremia were 
polymicrobial, with a fatal outcome in 11 of 26 (42%) sim- 
ilar to the outcome observed in monomicrobial bac- 
teremias (38/101,38%) (p = not significant, chi-square). 
In the first period (1976- 1983), polymicrobial bac- 
teremias were found in 9 of 38 cases (24%) with a mor- 
tality rate of 67% (619). In the second period 
(1984- 1995) polymicrobial bacteremias were found in 
17 of 89 cases (19%) with a fatal outcome in 5 of 17 
(29%). The results are comparable to those observed in 
monomicrobial bacteremias in the corresponding period 
of time (first period: episodes 29/38 [76%], mortality 
21/29 [72%]; second period: episodes 72/89 [Sl%], mor- 
tality 17/72 [23%], respectively) (P = not significant, 
chi-square). 
The most frequently associated organisms were: 
Staphylococcus aureus (n = lo), Streptococcus spp 
(n = 5), Escherichia coli (n = 4), Klebsiella (n = 3), 
Staphylococcus epidermidis (n = 3), non-aeruginosa 
Pseudomonas (n = l), Micrococcus (n = 1). Some 
episodes involved more than two organisms. 
The patients under and over 50 years of age were in com- 
parable number. The mortality rate was 47% (29/62) in 
patients over age 50 compared to 35% (20/57) in patients 
under age 50 (P = not significant, chi-square). 
Status of Underlying Disease 
The status of hematologic malignancy significantly 
affected the prognosis. The mortality rate in patients in 
relapse was 47% (25/53) compared to a mortality rate of 
32% (24/74) in patients not in relapse (P = 0.02, 
chi-square) . 
Antibiotic Therapy 
Table 4 analyzes the relations among inappropriate anti- 
biotic therapy, delayed antibiotic therapy, pneumonia, 
shock, and clinical outcome. The two groups of patients 
were again those treated before the introduction of third 
generation cephalosporin or imipenem-cilastatin and 
those who received these antibiotics. In the first group 
of patients (A) the empirical antibiotic therapy was inap- 
propriate in 11 of 38 episodes (29%). The incidence of 
pneumonia, shock and death were respectively 27 of 38 
(71%) 29 of 38 (76%) and 27 of 38 (71%). In the second 
group (B), including 89 episodes, the cases with inap- 
propriate antibiotic therapy were significantly reduced 
(Z/89, 2%, P < 0.0001). Similarly, the mortality was sig- 
nificantly reduced (22/W, 25%, P < 0.0001). 
The delay in starting the antibiotic therapy was 
important for the clinical outcome (see Table 4). A delay 
between the onset of fever that subsequently was proven 
to be due to P aeruginosa and starting of antibiotic 
Table 4. Relation among Inappropriate Antibiotic Therapy, Septic Shock, Pneumonia, 




Deaths Antibiotic Therapy Shock Pneumonia Delay Delay No Delay 
1976-l 983 (A) 38 
1984-I 995 (B) 89 
P-Value (A vs. B) 
Total 127 
*Delay vs. no delay, P < 0.0001. 
27/38 (71%) 11/38 (29%) 29/38 (76%) 27/38 (71%) 18/38 (47%) 15/l 8 (83%) 12/20 (60%) 
22/89 (25%) 2/89 (2%) 17/89 (19%) 34/89 (38%) 5/89 ( 5%) 4/5 (80%) 18/84 (2 1%) 
< 0.0001 < 0.0001 < 0.0001 < 0.001 < 0.0001 NS 0.0003 
49/l 27 (38%) 13/l 27 (10%) 46/127 (36%) 61/l 27 (48%) 23/l 27 (18%) 19/23 (83%) 30/l 04 (29%) 
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Table 5. Relation between Antibiotic Therapy and Outcome in Episodes of Pseudomonas aeruginosa Bacteremia 
Antibiotics 1976-1983 1984-1995 Mortality*(%) 
Broad-spectrum penicillin + aminoglycoside 7 2 6/9 (67) 
Others antibiotics 11 2 7/l 3 (53) 
Second generation cephalosporin + aminoglycoside 20 - 15/20 (75) 
Ceftazidime - 13 5/l 3 (38) 
Ceftazidime + aminoglycoside - 53 15/53 (28) 
Imipenem-cilastatin 6 O/6 (-) 
Imipenem-cilastatin + aminoglycoside 13 l/13 (8) 
*Ceftazidime vs. ceftazidime + aminoglycoside, P = not significant; imipenem vs. imipenem-cilastatin + aminoglycoside, P = not significant; ceftaridime t 
aminoglycoside vs. imipenem-cilastatin + aminoglycoside, P < 0.002. 
therapy was observed in 23 of 127 (18%) episodes. Dur- 
ing the study, the number of patients starting with delay 
the empirical antibiotic therapy progressively decreased 
from 47% in the first group to 5% of the second group 
(P < O.OOOl).The overall mortality at 48 and 96 hours 
was 21% and 30%, respectively. The time of institution of 
antibiotics had an effect on survival. At 48 and 96 hours, 
83% and 74% of patients treated without delay were alive, 
respectively, in contrast to 56.5% (P = 0.01, chi-square) 
and 43.5% (P = 0.01, &i-square) of patients who received 
delayed antibiotic therapy. 
The various antibiotic therapies employed through- 
out the study period are reported in Table 5. Of note, 
third generation cephalosporins and imipenem-cilastatin, 
alone or combined with aminoglycoside, have been rou- 
tinely used since 1984. In patients treated with these 
drugs, the mortality decreased (see Table 5). 
DISCUSSION 
Pseudomonas aeruginosa bacteremia is considered the 
most life-threatening of bacteremias. Its mortality rate in 
most series approaches 45 to 50%, but it often reaches 
60 to 70% in neutropenic patients with neoplastic dis- 
eases, with the highest fatality rate observed in patients 
with hematologic malignancies.6-8~11~1~~z1~z5~z6 In more recent 
years, the mortality rate due to )! aeruginosa in neu- 
tropenic patients has ranged between 31% and 42%.27,zs 
The 127 consecutive episodes here reported 
occurred in a homogeneous population of adult patients 
with hematologic malignancies, most of them being 
affected by acute leukemia, often in relapse, and charac- 
terized by severe and prolonged neutropenia. 
The overall cure rate found in this study (61.5%) is 
similar to that previously reported in neutropenic 
patients. I9 In a large lo-year study reported by Bodey et 
al,2o patients with hematologic malignancies had a cure 
rate of 62%, without significant variations of mortality 
in the last 5 years compared to the first 5 years of the 
study. In the present study, the authors observed a 
reduction in the rate of mortality in recent years from 
71% in the first period to 25% in the last period (see 
Table 4), which compares favorably with recently pub- 
lished data.27-29 This improvement may be related to a 
combination of factors: physicians’ previous experience, 
earlier diagnosis, and prompt starting of the empirical 
antibiotic treatment with antipseudomonal activity at 
the onset of clinical signs of infection. Moreover, the 
recent introduction of newer antibiotics may have played 
a role in the improved results. 
The present study demonstrates that the following 
factors have unfavorable prognostic significance: pneu- 
monia, septic shock, persistent and profound neutropenia, 
hematologic malignancy in relapse, delay in starting the 
antibiotic therapy, inappropriate empirical therapy. Con- 
comitant pneumonia, as previously observed,10~19~20 was 
associated with a high rate of mortality. Significantly bet- 
ter results have been obtained with bacteremia alone or 
associated with affected sites other than lung (see 
Table 1). In patients presenting septic shock, the mortal- 
ity rate was high, confirming the severity of this 
event.3~5-8~20~28-34 The role of neutropenia as a risk factor 
was also confirmed in the present series.35 Granulocyte 
recovery was important for a favorable outcome (see 
Table 2). Pseudomonas aeruginosa bacteremia has a 
rapid evolution, with a mortality rate, ranging between 
31% and 40% in the first 36 hours.lo,lZ This study con- 
firms its rapid course in neutropenic patients. However, 
important differences in prognosis were observed, 
depending on the interval between the onset of fever 
and the start of the antibiotic therapy. Probably the 
improvement of results is partly connected with the 
shortening of the interval between onset of infection and 
antipseudomonal therapy in recent years (see Table 4). 
An appropriate treatment was of great importance for 
the prognosis. In the last years, the number of patients 
receiving an inappropriate empirical treatment sharply 
decreased (see Table 4). Obviously, the definition of appro- 
priate empirical treatment is theoretic, and it does not 
take into account the actual in vitro efficacy against the 
offending pathogen (with the diagnostic methods 
presently available, the initial therapy remains truly empir- 
ical). Nevertheless, this definition was of practical value 
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as a prognostic factor, in that deaths occurred consider- 
ably more frequently in patients receiving an inappro- 
priate therapy (see Table 4). 
The introduction in more recent years of ceftazidime 
and imipenem-cilastatin, alone or associated with amino- 
glycosides, improved the results (see Table 5). The more 
frequently used combination has been ceftazidime plus 
amikacin. The results are similar to those reported by the 
EORTC International Antimicrobial Therapy Cooperative 
Group.36 No differences in outcome were found between 
patients who received either ceftazidime or imipenem- 
cilastatin alone versus the same drugs in combination 
with aminoglycosides. These data concur with findings 
reported by Pizza et al with initial ceftazidime monother- 
apy.37 Although no significant advantage was observed 
with the addition by aminoglycosides, combinations of 
active agents are recommended in prolonged neutropenia 
by many investigators, owing to the intrinsic aggressive- 
ness of l? aeruginosa, and to avoid the development of 
antibiotic resistance.38 Moreover, recent studies support 
the use of initial combination therapy to reduce the dura- 
tion of antibiotic therapy.39 A particularly low rate of mor- 
tality has been observed after the introduction of 
imipenem-cilastatin. 
Results show that early and more effective antibiotic 
therapy is able to improve the outcome of this formerly 
devastating complication in neutropenic patients. Recent 
reports on the re-emergence of I? aeruginosa in Europe 
and in Japan suggest that a continuous surveillance should 
be kept against this organism.z8~40 
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